SCHEMBL206487

SCHEMBL206487

CCCCCCCc1ccc(Nc2nc(-c3ccc(-c4ccccn4)s3)cs2)cc1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.52
SMN1; SMN2 Q16637 4/20 0.52
NFKB1 P19838 3/20 0.52
NFKB2 Q00653 3/20 0.52
KMT2A Q03164 3/20 0.52
RELA Q04206 3/20 0.52
NPSR1 Q6W5P4 2/20 0.52
MEN1 O00255 2/20 0.52
PPP1CA P62136 2/20 0.52
NR1I2 O75469 1/20 0.52
NR4A1 P22736 1/20 0.51
VCP P55072 1/20 0.51
NPY5R Q15761 2/20 0.48
CSNK2A1 P68400 1/20 0.47
NPC1 O15118 4/20 0.45
RAB9A P51151 3/20 0.45
HTT P42858 2/20 0.45
ADRB2 P07550 1/20 0.44
ADRB1 P08588 1/20 0.44
ADRB3 P13945 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL206530 1.00 MAPT (0.52) MAPTSMN1; SMN2NFKB1NFKB2KMT2A
SCHEMBL206699 0.91 MAPT (0.63) MAPTSMN1; SMN2NFKB1NFKB2KMT2A
SCHEMBL206259 0.91 MAPT (0.63) MAPTSMN1; SMN2NFKB1NFKB2KMT2A
SCHEMBL205471 0.87 MEN1 (0.51) MAPTSMN1; SMN2NFKB1NFKB2KMT2A
SCHEMBL207273 0.87 MEN1 (0.51) MAPTSMN1; SMN2NFKB1NFKB2KMT2A
SCHEMBL206055 0.83 ALDH1A1 (0.51) MAPTSMN1; SMN2KMT2ANPSR1MEN1
SCHEMBL206182 0.83 ALDH1A1 (0.51) MAPTSMN1; SMN2KMT2ANPSR1MEN1
SCHEMBL14458394 0.79 MAPT (0.63) MAPTSMN1; SMN2NFKB1NFKB2KMT2A
SCHEMBL12298002 0.79 VCP (0.81) MAPTSMN1; SMN2NFKB1NFKB2KMT2A
SCHEMBL12297308 0.79 MAPT (0.63) MAPTSMN1; SMN2NFKB1NFKB2KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120108576-A1 THIAZOLE COMPOUNDS AND METHODS OF USE ACHILLION PHARMACEUTICALS, INC. (US) 2012-05-03 US disclosed
US-20120108576-A1 THIAZOLE COMPOUNDS AND METHODS OF USE ACHILLION PHARMACEUTICALS, INC. (US) 2012-05-03 US disclosed
US-20120108576-A1 THIAZOLE COMPOUNDS AND METHODS OF USE ACHILLION PHARMACEUTICALS, INC. (US) 2012-05-03 US disclosed
US-8088806-B2 Thiazole compounds and methods of use ACHILLION PHARMACEUTICALS, INC. (US) 2012-01-03 US disclosed
US-8088806-B2 Thiazole compounds and methods of use ACHILLION PHARMACEUTICALS, INC. (US) 2012-01-03 US disclosed
US-8088806-B2 Thiazole compounds and methods of use ACHILLION PHARMACEUTICALS, INC. (US) 2012-01-03 US disclosed
US-20070004711-A1 Thiazole compounds and methods of use ACHILLION PHARMACEUTICALS, INC. 2007-01-04 US disclosed
US-20070004711-A1 Thiazole compounds and methods of use ACHILLION PHARMACEUTICALS, INC. 2007-01-04 US disclosed
US-20070004711-A1 Thiazole compounds and methods of use ACHILLION PHARMACEUTICALS, INC. 2007-01-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120108576-A1 THIAZOLE COMPOUNDS AND METHODS OF USE PIGS, CPT1A, SLC10A1 MAPT 2207/4885SMN1; SMN2 3252/4885NFKB1 3007/4885
US-20070004711-A1 Thiazole compounds and methods of use PIGS, CPT1A, SLC10A1 MAPT 2207/4885SMN1; SMN2 3252/4885NFKB1 3007/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.